Literature DB >> 10486928

Diva vaccines that reduce virus transmission.

J T van Oirschot1.   

Abstract

This brief review deals with the effect of diva (Differentiating Infected from VAccinated individuals) vaccines (also termed marker vaccines) on transmission of herpesviruses and pestiviruses in swine and cattle. Pseudorabies and bovine herpesvirus 1 diva vaccines have been demonstrated to reduce transmission of wild-type virus in populations of pigs and cattle in the laboratory as well as in the field. A subunit diva vaccine based on the immunodominant E2 protein of classical swine fever virus that is expressed in the baculovirus system may reduce transmission of wild-type virus among pigs and also transmission from mother to foetuses. A similar diva vaccine against bovine virus diarrhoea infections protected sheep against transplacental transmission of antigenically homologous wild-type virus. Diva vaccines along with their companion diagnostic tests can play a role in control of infections, ultimately leading to eradication of viruses.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10486928     DOI: 10.1016/s0168-1656(99)00121-2

Source DB:  PubMed          Journal:  J Biotechnol        ISSN: 0168-1656            Impact factor:   3.307


  33 in total

1.  In vitro and in vivo relevance of infectious laryngotracheitis virus gJ proteins that are expressed from spliced and nonspliced mRNAs.

Authors:  Walter Fuchs; Dorothee Wiesner; Jutta Veits; Jens P Teifke; Thomas C Mettenleiter
Journal:  J Virol       Date:  2005-01       Impact factor: 5.103

2.  Enzyme-linked immunosorbent assay using a virus type-specific peptide based on a subdomain of envelope protein E(rns) for serologic diagnosis of pestivirus infections in swine.

Authors:  J P Langedijk; W G Middel; R H Meloen; J A Kramps; J A de Smit
Journal:  J Clin Microbiol       Date:  2001-03       Impact factor: 5.948

3.  Vaccination with DNA plasmids expressing Gn coupled to C3d or alphavirus replicons expressing gn protects mice against Rift Valley fever virus.

Authors:  Nitin Bhardwaj; Mark T Heise; Ted M Ross
Journal:  PLoS Negl Trop Dis       Date:  2010-06-22

Review 4.  Diagnosis and control of peste des petits ruminants: a comprehensive review.

Authors:  V Balamurugan; D Hemadri; M R Gajendragad; R K Singh; H Rahman
Journal:  Virusdisease       Date:  2013-11-27

5.  Characterization of a serologic marker candidate for development of a live-attenuated DIVA vaccine against porcine reproductive and respiratory syndrome virus.

Authors:  Hiep L X Vu; Byungjoon Kwon; Marcelo de Lima; Asit K Pattnaik; Fernando A Osorio
Journal:  Vaccine       Date:  2013-07-23       Impact factor: 3.641

6.  Population-based analysis of Actinobacillus pleuropneumoniae ApxIVA for use as a DIVA antigen.

Authors:  Ciaragh O'Neilla; Sophie C P Jones; Janine T Bossé; Conrad M Watson; Susanna M Williamson; Andrew N Rycroft; J Simon Kroll; Helen M Hartley; Paul R Langford
Journal:  Vaccine       Date:  2010-05-16       Impact factor: 3.641

7.  A glycoprotein E gene-deleted bovine herpesvirus 1 as a candidate vaccine strain.

Authors:  M Weiss; M C S Brum; D Anziliero; R Weiblen; E F Flores
Journal:  Braz J Med Biol Res       Date:  2015-07-21       Impact factor: 2.590

8.  The Bluetongue Disabled Infectious Single Animal (DISA) Vaccine Platform Based on Deletion NS3/NS3a Protein Is Safe and Protective in Cattle and Enables DIVA.

Authors:  Piet A van Rijn; Mieke A Maris-Veldhuis; René G P van Gennip
Journal:  Viruses       Date:  2021-05-07       Impact factor: 5.048

9.  A review of vaccine development and research for industry animals in Korea.

Authors:  Nak-Hyung Lee; Jung-Ah Lee; Seung-Yong Park; Chang-Seon Song; In-Soo Choi; Joong-Bok Lee
Journal:  Clin Exp Vaccine Res       Date:  2012-07-31

10.  Modulation of Humoral and Cell-Mediated Immunity Against Avian Influenza and Newcastle Disease Vaccines by Oral Administration of Salmonella enterica Serovar Typhimurium Expressing Chicken Interleukin-18.

Authors:  Md Masudur Rahman; Erdenebileg Uyangaa; Seong Kug Eo
Journal:  Immune Netw       Date:  2013-02-28       Impact factor: 6.303

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.